- Home
- NGS vs RLMD Comparison
NGS vs RLMD Comparison
Compare NGS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGS | RLMD |
|---|---|---|
| Founded | 1998 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 354.3M | 307.3M |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | NGS | RLMD |
|---|---|---|
| Price | $32.18 | $4.22 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $35.67 | $5.50 |
| AVG Volume (30 Days) | 96.5K | ★ 1.2M |
| Earning Date | 11-10-2025 | 11-13-2025 |
| Dividend Yield | ★ 1.37% | N/A |
| EPS Growth | ★ 14.85 | N/A |
| EPS | ★ 1.47 | N/A |
| Revenue | ★ $166,824,000.00 | N/A |
| Revenue This Year | $9.50 | N/A |
| Revenue Next Year | $13.88 | N/A |
| P/E Ratio | $21.87 | ★ N/A |
| Revenue Growth | ★ 9.53 | N/A |
| 52 Week Low | $16.73 | $0.24 |
| 52 Week High | $32.93 | $5.12 |
Technical Indicators
Market Signals| Indicator | NGS | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 64.59 | 64.70 |
| Support Level | $30.54 | $3.70 |
| Resistance Level | $32.05 | $4.56 |
| Average True Range (ATR) | 1.11 | 0.49 |
| MACD | 0.08 | -0.07 |
| Stochastic Oscillator | 77.78 | 38.03 |
Price Performance
Historical ComparisonAbout NGS Natural Gas Services Group Inc.
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.